Multi-Year Contracts With Public Schools And Hospitals Will Expand Markets

Published
01 Jun 25
Updated
16 Aug 25
AnalystConsensusTarget's Fair Value
US$9.50
18.4% undervalued intrinsic discount
16 Aug
US$7.75
Loading
1Y
117.1%
7D
6.3%

Author's Valuation

US$9.5

18.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on16 Aug 25
Fair value Increased 32%

The analyst price target for Evolv Technologies Holdings has been raised significantly, driven by a Q2 earnings beat, upgraded FY25 revenue guidance, improved business outlook following regulatory clarity and management changes, as well as momentum across key industry verticals, lifting the consensus fair value from $7.19 to $9.50. Analyst Commentary Q2 earnings beat on both revenue and AEBITDA, leading to upgraded financial forecasts for FY25.